top of page

Skyhawk News

Skyhawk's proprietary platform revolutionizes disease treatment by developing small molecule therapeutics that correct RNA expression

March 25, 2024

Skyhawk Has Advanced to Multiple Ascending Dose in it’s SKY-0515 Huntington’s Trial

Skyhawk Has Advanced to Multiple Ascending Dose in it’s SKY-0515 Huntington’s Trial

SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform.

September 7, 2022

Drugging RNA with Pills : Small Molecules for a Big Frontier

Drugging RNA with Pills : Small Molecules for a Big Frontier

Can biotechnology startups turn what were once accidental discoveries into a purposeful way to hit hard-to-reach disease targets?

September 14, 2021

Skyhawk Therapeutics Completes New Investment Round

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates in

December 22, 2020

$40M up front: Skyhawk takes flight with Vertex deal

$40M up front: Skyhawk takes flight with Vertex deal

Skyhawk Therapeutics Inc., one of the early leaders in developing small-molecule drugs that target RNA, closed out the year with yet another

September 30, 2020

The Endpoints 11 : Here are some of the most promising startups in biotech. And Covid-19 isn’t ...

The Endpoints 11 : Here are some of the most promising startups in biotech. And Covid-19 isn’t ...

The Endpoints 11 : Here are some of the most promising startups in biotech. And Covid-19 isn’t going to stop them John Carroll : Editor &...

May 12, 2020

Merck doubles down on Skyhawk’s tech to drug RNA, promising $600M per autoimmune, metabolic target

Merck doubles down on Skyhawk’s tech to drug RNA, promising $600M per autoimmune, metabolic target

Ear­ly col­lab­o­ra­tions with big-name part­ners lent Sky­hawk Ther­a­peu­tics both the en­dorse­ments and the cap­i­tal to pur­sue a small

December 16, 2019

The 20 Startups to Watch in Boston in 2020

The 20 Startups to Watch in Boston in 2020

Below are the 20 Startups to Watch in 2020. Based on factors like funding, partnerships, awards, technology licenses and more

October 23, 2023

Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small

Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small

SKY-0515 is a small molecule RNA splicing modifier developed through the company’s novel SKYSTAR®

July 7, 2022

Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets

Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets

Companies to leverage Skyhawk’s proprietary SkySTAR™ platform to discover and develop novel small molecules that modulate RNA splicing to...

September 14, 2021

Bill Haney adds another $133M to Skyhawk’s coffers, as the RNA startup guns for the clinic

Bill Haney adds another $133M to Skyhawk’s coffers, as the RNA startup guns for the clinic

A few years after becoming one of the first major biotechs out to drug RNA with small molecules, serial entrepreneur and filmmaker Bill Hane

December 22, 2020

A busy, buzzy Vertex finds a high-profile partner in the RNA-drugging world to launch a fresh ...

A busy, buzzy Vertex finds a high-profile partner in the RNA-drugging world to launch a fresh ...

A busy, buzzy Vertex finds a high-profile partner in the RNA-drugging world to launch a fresh discovery effort

May 12, 2020

Skyhawk Therapeutics boosts Merck collab pact with added targets, upfront and biobucks

Skyhawk Therapeutics boosts Merck collab pact with added targets, upfront and biobucks

Merck has decided to double down on its research pact with startup Skyhawk Therapeutics as it expands the deal to now also cover autoimmune

April 6, 2020

The 20 under 40 : Inside the next generation of biopharma leaders

The 20 under 40 : Inside the next generation of biopharma leaders

Inside the next generation of biopharma leaders – Endpoints News

November 12, 2019

Celgene execs shell out $92M cash for a pair of R&D deals that will fit perfectly in their new home

Celgene execs shell out $92M cash for a pair of R&D deals that will fit perfectly in their new home

With Bris­tol-My­ers Squibb’s Cel­gene buy­out all but com­plete, the BD teams are work­ing in per­fect syn­chrony now.

May 17, 2023

Drugging RNA

Drugging RNA

Small molecules that target messenger RNA have therapeutic potential, but the field still lacks an unqualified success.

July 6, 2022

Bill Haney’s latest startup scores deal from Sanofi its newest Big Pharma partner, with $54M upfront

Bill Haney’s latest startup scores deal from Sanofi its newest Big Pharma partner, with $54M upfront

A heavily financed biotech looking to drug RNA with small molecules is adding yet another company to its Big Pharma shortlist.

April 13, 2021

Skyhawk Therapeutics Expands Leadership Team, Appointing Elliot Ehrich MD as President

Skyhawk Therapeutics Expands Leadership Team, Appointing Elliot Ehrich MD as President

Skyhawk Therapeutics Expands Leadership Team, Appointing Elliot Ehrich MD as President and Graeme Smith PhD as SVP NonClinical Development

December 22, 2020

Vertex joins Skyhawk’s roster of A-list partners, securing options on RNA splicing modulators

Vertex joins Skyhawk’s roster of A-list partners, securing options on RNA splicing modulators

Vertex will take full responsibility for development and commercialization of assets it licenses from Skyhawk Therapeutics.

May 12, 2020

Skyhawk Therapeutics Announces Expansion of its Collaboration Agreement with Merck

Skyhawk Therapeutics Announces Expansion of its Collaboration Agreement with Merck

Skyhawk Therapeutics Announces Expansion of its Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modula

February 24, 2020

Experienced Business Leader in Biopharmaceutical Industry Joins as Chief Operating Officer

Experienced Business Leader in Biopharmaceutical Industry Joins as Chief Operating Officer

Dr. Terrance Connolly brings over 20 years of biotech operations and business development experience to his role as Chief Operating Officer

bottom of page